Latest Safety News

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

MinRex Resources has secured all approvals to commence a fully funded drilling program targeting high-priority copper-gold deposits at the Fraser Range Project in Western Australia, aiming to unlock significant exploration potential.

Neurizon Therapeutics has announced the successful completion of its Open-Label Extension study for NUZ-001 in ALS, revealing significant survival benefits and strong tolerability. The company is on track to release top-line results in Q3 2025 and advance to a pivotal Phase 2/3 trial.

Boom Logistics reports robust 3Q FY25 results with revenue and profit gains led by renewables projects, while pausing its share buy-back after meeting targets.

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.

Lotus Resources has received critical regulatory approval from Malawi’s Atomic Energy Regulatory Authority to resume uranium mining at its Kayelekera project, paving the way for production restart in the third quarter of 2025.

Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.

SenSen Networks has extended its contract with Brisbane City Council for kerb management and enforcement solutions, including a large-scale rollout of its innovative SenPIC technology, in a deal valued at an estimated $8 million over four years.

Nyrada Inc. has cleared the Safety Review Committee’s scrutiny for its Phase I clinical trial, progressing to the third dosing cohort of its promising neuroprotective and cardioprotective drug candidate NYR-BI03.

Saferoads Holdings has finalised the sale of its Road Safety Rentals assets, repaid all related debts, and announced a fully franked 10 cent special dividend for shareholders.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.